NasdaqCM - Nasdaq Real Time Price USD
Achieve Life Sciences, Inc. (ACHV)
At close: 4:00 PM EDT
After hours: 4:34 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
25,371.0000
27,250.0000
40,800.0000
33,094.0000
14,750.0000
--
Operating Income
-25,371.0000
-27,250.0000
-40,800.0000
-33,094.0000
-14,750.0000
--
Net Non Operating Interest Income Expense
-1,514.0000
-2,028.0000
-1,590.0000
17.0000
69.0000
--
Other Income Expense
-654.0000
-537.0000
40.0000
-75.0000
-49.0000
--
Pretax Income
-27,539.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Net Income Common Stockholders
-27,539.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Diluted NI Available to Com Stockholders
-27,539.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Basic EPS
-1.07
-1.50
-4.00
-4.08
-5.42
--
Diluted EPS
-1.07
-1.50
-4.00
-4.08
-5.42
--
Basic Average Shares
25,425.9040
19,827.3540
10,593.0340
8,119.8360
2,718.9090
--
Diluted Average Shares
25,425.9040
19,827.3540
10,593.0340
8,119.8360
2,718.9090
--
Total Expenses
25,371.0000
27,250.0000
40,800.0000
33,094.0000
14,750.0000
--
Net Income from Continuing & Discontinued Operation
-27,539.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Normalized Income
-26,902.0000
-29,287.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Interest Income
1,671.0000
825.0000
199.0000
17.0000
69.0000
--
Interest Expense
3,185.0000
2,853.0000
1,789.0000
--
--
--
Net Interest Income
-1,514.0000
-2,028.0000
-1,590.0000
17.0000
69.0000
--
EBIT
-24,354.0000
-26,962.0000
-40,561.0000
-33,152.0000
-14,730.0000
--
EBITDA
-24,125.0000
-26,734.0000
-40,325.0000
-32,902.0000
-14,475.0000
--
Reconciled Depreciation
229.0000
228.0000
236.0000
250.0000
255.0000
--
Net Income from Continuing Operation Net Minority Interest
-27,539.0000
-29,815.0000
-42,350.0000
-33,152.0000
-14,730.0000
--
Total Unusual Items Excluding Goodwill
-637.0000
-528.0000
--
--
--
--
Total Unusual Items
-637.0000
-528.0000
--
--
--
--
Normalized EBITDA
-23,488.0000
-26,206.0000
-40,325.0000
-32,902.0000
-14,475.0000
--
12/31/2019 - 10/12/1995
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACRV Acrivon Therapeutics, Inc.
7.75
+1.97%
MDNAF Medicenna Therapeutics Corp.
1.6700
-2.91%
MURA Mural Oncology plc
3.7200
+7.83%
ETNB 89bio, Inc.
8.61
+7.36%
ACXP Acurx Pharmaceuticals, Inc.
2.0500
+0.49%
INZY Inozyme Pharma, Inc.
5.31
-1.12%
ELVN Enliven Therapeutics, Inc.
28.12
+1.08%
NGENF NervGen Pharma Corp.
1.7800
-1.11%
DNTH Dianthus Therapeutics, Inc.
27.97
+1.56%
AURA Aura Biosciences, Inc.
10.25
+3.96%